Mall of America

ASID Names Interior Designer Stephany Eaton First & Second Place Awards for Design Excellence

Retrieved on: 
Monday, January 2, 2023
Health care, Corporation, Mall of America, ASID, Interior, American Society of Interior Designers, Minnetonka, Minnesota, Sustainable design, International Design Excellence Awards, Northwestern Knitting Company Factory building, Ameriprise Financial, Mall, Boston Architectural College, Paisley Park Records, Society, Professional, Chemistry, Property management, Interior design, Retail

MINNEAPOLIS, Jan. 2, 2023 /PRNewswire-PRWeb/ -- Stephany Eaton, founder of PureAlchemy Design, has been awarded first and second place awards by the https://mn.asid.org/news/2022-design-excellence-award-winnersAmerican Society of Interior Designers (ASID), Minnesota chapter. ASID awarded Eaton first-place in the Healthcare category for her work on https://purealchemydesign.com/commercial-interiors-portfolio/pine-ridge-... Ridge Dental in Zimmerman, MN and second-place in the Corporate (small) category for her work on https://purealchemydesign.com/commercial-interiors-portfolio/professiona... Data Analysts, a consultancy in Minneapolis.

Key Points: 
  • Stephany Eaton, founder of PureAlchemy Design, has been awarded first and second place awards by the American Society of Interior Designers (ASID), Minnesota chapter.
  • MINNEAPOLIS, Jan. 2, 2023 /PRNewswire-PRWeb/ -- Stephany Eaton, founder of PureAlchemy Design, has been awarded first and second place awards by the https://mn.asid.org/news/2022-design-excellence-award-winners American Society of Interior Designers (ASID) , Minnesota chapter.
  • A professional association for interior designers, ASID seeks to advance the interior design profession and communicate the impact of design on the human experience.
  • The Design Excellence Awards took place on November 3rd at International Market Square in Minneapolis.

Wisdom Gaming Studios Becomes the Home for T-Wolves Gaming

Retrieved on: 
Tuesday, December 20, 2022
K League, Mall of America, NBA, Take-Two Interactive, Dash Radio, SPS, Minnesota Timberwolves, AT, International, Partnership, Sony Interactive Entertainment, Wilson, NBA 2K League, Senior, Foot, Multimedia, SAP, Culture, AT&T, TTWO, Anheuser-Busch, Esports, Video game, Sport, Wisdom, Mall, Lynx, Snickers, Sport1, Timber Wolf

BLOOMINGTON, Minn., Dec. 20, 2022 /PRNewswire/ -- The Minnesota Timberwolves and Wisdom Gaming, the emerging leader in esports and gaming entertainment, today announced the company's flagship gaming and esports venue, Wisdom Gaming Studios, will be the new home for T-Wolves Gaming, the official esports team of the Minnesota Timberwolves. Kicking off in 2023, this marks the first formal partnership between these two Minnesota-based organizations. Timberwolves fans can interact  with T-Wolves Gaming players and experience the best of esports entertainment at the Mall of America®.

Key Points: 
  • BLOOMINGTON, Minn., Dec. 20, 2022 /PRNewswire/ -- The Minnesota Timberwolves and Wisdom Gaming, the emerging leader in esports and gaming entertainment, today announced the company's flagship gaming and esports venue, Wisdom Gaming Studios, will be the new home for T-Wolves Gaming, the official esports team of the Minnesota Timberwolves.
  • "We're thrilled to partner with T-Wolves Gaming and establish their new home at Wisdom Gaming Studios," said Steve LaCroix, President of Wisdom Gaming.
  • T-Wolves Gaming will begin building out their new space  in Wisdom Gaming Studios ahead of the 2023 NBA 2k season.
  • For more information on Wisdom Gaming Studios and T-Wolves Gaming, please visit wisdomstudios.gg.

Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Retrieved on: 
Tuesday, December 20, 2022
Molecule, Health care, Degenerative disease, Target, History, Sleep, Discovery, Diabetes, Risk, Metabolism, Mall of America, R, News, Medication, Health, Therapy, Pharmaceutical formulation, Research, Drug, Pharmaceutical industry, Medical device, Surveying, Oil, Marketing, Obesity

Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Key Points: 
  • Obesity Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    This latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Drugs In Development, 2022, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.
  • Pharmaceutical and Healthcare latest pipeline guide Obesity - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects.
  • - The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Retrieved on: 
Tuesday, December 20, 2022
Molecule, Health care, Target, Psoriasis, History, Risk factor, Psoriatic arthritis, The, Discovery, Low back pain, Mall of America, R, News, Medication, Human musculoskeletal system, Finger, Therapy, Nonsteroidal anti-inflammatory drug, Pharmaceutical formulation, Arthritis, Research, Pharmaceutical industry, Medical device, Surveying, Oil, Marketing

Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Key Points: 
  • Psoriatic Arthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    This latest Pharmaceutical and Healthcare disease pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides an overview of the Psoriatic Arthritis (Musculoskeletal Disorders) pipeline landscape.
  • Pharmaceutical and Healthcare latest pipeline guide Psoriatic Arthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Psoriatic Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Psoriatic Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects.
  • - The pipeline guide evaluates Psoriatic Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Retrieved on: 
Tuesday, December 20, 2022
Molecule, Health care, Target, History, Cervical cancer, HPV, Bleeding, Discovery, Oncology, Mall of America, Spotting, R, News, Medication, Menopause, Chemotherapy, Therapy, Pharmaceutical formulation, Research, Birth control, Pharmaceutical industry, Medical imaging, Oil, Surveying, Marketing, Phase II, Development

Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Key Points: 
  • Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    This latest Pharmaceutical and Healthcare disease pipeline guide Cervical Cancer - Drugs In Development, 2022, provides an overview of the Cervical Cancer (Oncology) pipeline landscape.
  • Pharmaceutical and Healthcare latest pipeline guide Cervical Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Cervical Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Cervical Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Cervical Cancer and features dormant and discontinued projects.
  • - The pipeline guide evaluates Cervical Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Retrieved on: 
Tuesday, December 20, 2022
Molecule, Health care, Target, Exocrine gland, History, MRI, Drug, Abdomen, Biopsy, CT, Discovery, Neck, Spinal cord, Oncology, Mall of America, R, News, Medication, Bone pain, Therapy, Movement, Pharmaceutical formulation, Research, Cancer, Pharmaceutical industry, Medical imaging, Surveying, Medical device, Oil, Marketing, Neuroblastoma, Phase II

Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Key Points: 
  • Neuroblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    This latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Drugs In Development, 2022, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.
  • Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects.
  • - The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Retrieved on: 
Tuesday, December 20, 2022
Molecule, RSV, Health care, Target, History, Respiratory disease, Discovery, Mall of America, Infection, Bronchiolitis, Inflammation, R, News, Medication, Pneumonia, Ear, Therapy, Fever, Cough, Pharmaceutical formulation, Stuffy, Respiratory syncytial virus, Lung, Research, Vaccine, Pharmaceutical industry, Surveying, Marketing

NEW YORK, Dec. 20, 2022 /PRNewswire/ -- Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Key Points: 
  • NEW YORK, Dec. 20, 2022 /PRNewswire/ -- Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    This latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.
  • Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects.
  • - The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Retrieved on: 
Tuesday, December 20, 2022
Molecule, Health care, Spleen, Target, History, Radiation, Risk factor, Bruise, Liver, Acute lymphoblastic leukemia, Anemia, Discovery, Acute leukemia, Degenerative disease, Oncology, Mall of America, R, News, Medication, Lymph, Bone pain, Therapy, Infection, Working Formulation, Lymphocyte, Research, Cancer, ALL, Oil, Pharmaceutical industry, Surveying, Marketing

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Key Points: 
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
    This latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drugs In Development, 2022, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline landscape.
  • Treatment includes chemotherapy, transfusions, transplant and medications.c
    Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects.
  • - Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology).

Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Tuesday, December 13, 2022
Technology, Clinical Trials, Professional Services, Biotechnology, Health, Data Analytics, Pharmaceutical, Artificial Intelligence, Oncology, Security (finance), Therapy, Probability, Standard of care, Parpi, Prognosis, Estrogen, Judgement, TNBC, Lung, Glioblastoma, Central nervous system, IND, Diagnosis, ATRT, HER2, Patient, DNA, Mall of America, Annual report, ADC, Research, Drug Quality and Security Act, Triple-negative breast cancer, Breast cancer, FDA, DDR, SOC, IC50, PARP, COVID-19, Survival, Metadata, Clinical trial, Risk, Brain, Breast, A.I, PDX, Marketing, Machine learning, Pancreatic cancer, CNS, Neoplasm, Medical imaging, Pharmaceutical industry, Progesterone, Olaparib, Lantern

platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has expanded development of its drug candidate LP-184 to include Triple Negative Breast Cancer (TNBC), one of the most aggressive and malignant forms of breast cancer.

Key Points: 
  • platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it has expanded development of its drug candidate LP-184 to include Triple Negative Breast Cancer (TNBC), one of the most aggressive and malignant forms of breast cancer.
  • New positive preclinical data on the anti-tumor potency of LP-184 for TNBCs was recently presented at the San Antonio Breast Cancer Symposium (SABCS) 2022.
  • As many as 20% of all breast cancers are TNBCs, which are tumors that do not express receptors for Estrogen, Progesterone, or HER2.
  • LP-184 had low nanomolar potency (average IC50 of 297nM) when tested across a panel of 4 TNBC breast cancer cell lines.

Ataxin 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 8, 2022
Genetics, Pharmaceutical, Health, Molecule, Spinocerebellar ataxia, Therapy, Research and development, R, Key, EC, Ataxin 3, Product description, ATXN3, Research, Machado–Joseph disease, Mall of America, Route of administration, History, Administration, News, SCA3, Pharmaceutical industry, Medical device

The "Ataxin 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Ataxin 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • This report provides in depth analysis on Ataxin 3 (Machado Joseph Disease Protein 1 or Spinocerebellar Ataxia Type 3 Protein or SCA3 or ATXN3 or EC 3.4.19.12) targeted pipeline therapeutics.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.